A Phase 2 Study to Assess the Safety and Efficacy of Umbralisib in Patients With Chronic Lymphocytic Leukemia (cll) Who Are Intolerant to Prior Btk or Pi3k Delta Inhibitor Therapy
Year: 2019
Type: article
Study design: Clinical Trial
Source: Hematological Oncology
DOI: 10.1002/hon.56_2629
Authors: A.R. Mato, S.J. Schuster, N. Lamanna, J.M. Pagel, I.W. Flinn, J. Barrientos, J.A. Reeves, B.D. Cheson, P.M. Barr, S. Kambhampati, F. Lansigan, J.J. Pu, A. Skarbnik, G. Fonseca, C. Dorsey, N.M. LaRatta, H. Weissbrot, J. Svoboda, E.T. Luning Prak, P. Tsao, A. Sitlinger, D. Paskalis, P. Sportelli, H.P. Miskin, M.S. Weiss, D.M. Brander
Institutions: Memorial Sloan Kettering Cancer Center, Abramson Cancer Center, University of Pennsylvania, Columbia University Irving Medical Center, Swedish Medical Center, Sarah Cannon, Tennessee Oncology, Northwell Health, Georgetown University Medical Center, Georgetown Lombardi Comprehensive Cancer Center, University of Rochester Medicine, University of Rochester, Research Medical Center, Dartmouth–Hitchcock Medical Center, Pennsylvania State University, Penn State Milton S. Hershey Medical Center, Florida Cancer Specialists & Research Institute, Duke Medical Center, TG Therapeutics, Inc. (United States)
Language: English
Subfield: Genetics (clinical)
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2951135765